U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H9F5N3O4S.Na
Molecular Weight 433.286
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of T-900607 SODIUM

SMILES

[Na+].COC1=C(NC(N)=O)C=C([N-]S(=O)(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C=C1

InChI

InChIKey=AJSKTEZZBVEPLY-UHFFFAOYSA-N
InChI=1S/C14H9F5N3O4S.Na/c1-26-7-3-2-5(4-6(7)21-14(20)23)22-27(24,25)13-11(18)9(16)8(15)10(17)12(13)19;/h2-4H,1H3,(H3,20,21,23);/q-1;+1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H10F5N3O4S
Molecular Weight 411.304
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

T-900607 is a pentafluorophenylsulphonamide derivative patented by Tularik Inc. as antiproliferative agent. Antitumor mechanism of T900607 is similar to the vinca alkaloids in terms of disruption of microtubule polymerization but uniquely causes a specific covalent modification of β-tubulin. In preclinical studies, T900607 was shown to bind irreversibly and specifically to the β1, β2, and β4 isotypes of β-tubulin is not a substrate for p-glycoprotein drug pump and has activity in the preclinical setting in MDR models. T900607 was evaluated in human tumor xenografts and showed activity in MX-1, MCF-7, and MCF-7/ADR mammary, C13 ovarian, HT 29 colon, and Caki-1 renal carcinoma as well as lymphoblastic leukemia, with equal or more efficacious effects compared to vinblastine, doxorubicin and paclitaxel. In a clinical trial, T-900607 shows significant toxicity, consisting of thrombocytopenia, nausea/vomiting, fatigue, and apparent cardiac toxicity.

Approval Year

PubMed

PubMed

TitleDatePubMed
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130.
2005 Oct
Patents

Patents

Sample Use Guides

130 mg/m^2 on day 1 of an every three week cycle.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:08:07 GMT 2023
Edited
by admin
on Fri Dec 15 16:08:07 GMT 2023
Record UNII
4L9Y5UF2Q2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
T-900607 SODIUM
Common Name English
T900607 SODIUM
Common Name English
N-(2-METHOXY-5-(PENTAFLUOROPHENYLSULFONAMIDO)PHENYL)UREA SODIUM
Systematic Name English
T900607-SODIUM
Code English
Code System Code Type Description
FDA UNII
4L9Y5UF2Q2
Created by admin on Fri Dec 15 16:08:07 GMT 2023 , Edited by admin on Fri Dec 15 16:08:07 GMT 2023
PRIMARY
DRUG BANK
DBSALT002130
Created by admin on Fri Dec 15 16:08:07 GMT 2023 , Edited by admin on Fri Dec 15 16:08:07 GMT 2023
PRIMARY
PUBCHEM
71587683
Created by admin on Fri Dec 15 16:08:07 GMT 2023 , Edited by admin on Fri Dec 15 16:08:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID70180823
Created by admin on Fri Dec 15 16:08:07 GMT 2023 , Edited by admin on Fri Dec 15 16:08:07 GMT 2023
PRIMARY
CAS
261944-77-8
Created by admin on Fri Dec 15 16:08:07 GMT 2023 , Edited by admin on Fri Dec 15 16:08:07 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY